Rapport Therapeutics to Participate in Upcoming Investor Conferences
BOSTON and SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ('Rapport' or the 'Company'), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in three upcoming investor conferences.
Jones Trading Virtual CNS Symposium - fireside chat on Tuesday, April 29, 2025, from 11:00-11:25am ET.
Citizens JMP 2025 Life Sciences Conference (New York City) - fireside chat on Thursday, May 8, 2025, from 1:30-1:55pm ET.
Mizuho Neuro & Ophthalmology Summit 2025 (New York City) - investor meetings on Wednesday, May 21, 2025.
Interested parties may access the live and archived webcasts of the Jones Trading and Citizens JMP fireside chats under the 'Investors' section of the company's website at: https://investors.rapportrx.com.
About Rapport TherapeuticsRapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company's founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport's RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport's precision neuroscience pipeline includes the Company's lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
ContactJulie DiCarloHead of Communications & IRRapport Therapeuticsjdicarlo@rapportrx.com
Source: https://www.rapportrx.com/Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Terra Metals Inc. and Lunda Resources Confirm 96.5% Copper Recovery and Solar-Powered Green Production at Kalaba Project
CHARLOTTE, N.C. and LUSAKA, Zambia, June 09, 2025 (GLOBE NEWSWIRE) -- Terra Metals Inc., in partnership with its Zambian subsidiary Lunda Resources Ltd., is proud to announce a major metallurgical breakthrough at the Kalaba Copper Project in Northwestern Zambia. Independent testing conducted by Dr. Yotamu Hara of YCS Sustainable Solutions Ltd. confirms flotation recoveries exceeding 96.5%, with concentrate grades of 26.91% Cu—a remarkable result for oxide-dominant ore. Technical Highlights: 96.52% cumulative copper recovery using flotation (see p. 30 of Hara Report), with sulphide concentrates at 26.91% Cu and oxide concentrates at 4.31% Cu. Flotation made possible through advanced chemistry, particularly the use of CMC depressants to manage high talc content (up to 54%), previously considered a major processing barrier. The ore's upgrade potential allows for low-cost leaching via solvent extraction, positioning Kalaba among Africa's lowest-cost green copper producers. An NI 43-101-compliant resource estimate is expected to be released before the end of July 2025. A Model for Green Critical Minerals: Full environmental clearance has been granted by ZEMA (Zambia Environmental Management Agency). A 5 MW solar energy facility has been completed and approved, with plans to expand to 100 MW—enabling carbon-neutral production of copper and cobalt. Terra Metals and its partners will become Zambia's first large-scale producers of green critical metals, powered almost entirely by solar energy. Traditional & Community Support: Terra Metals acknowledges the tremendous support of His Royal Highness Senior Chief Sailunga and Chief Ntambu of the Lunda people. Their leadership and collaboration have played a vital role in advancing the Kalaba Project with integrity and respect for local communities. Regional Upside: In addition to Kalaba, the company holds a large-scale exploration license through Central Africa Renewable Energy, covering a prospective copper-cobalt zone immediately south of Ivanhoe's world-class Kamoa-Kakula Mine in the DRC Copperbelt. Chairman's Statement: 'This isn't just a technical success—it's a declaration that Zambia can lead in responsible, solar-powered production of the world's most critical minerals. Kalaba is proof that innovation, sustainability, and community partnership can deliver real value.'— Mumena Mushinge, Chairman, Terra Metals Inc. and Lunda Resources. Next Milestones: NI 43-101 Report expected before July 31, 2025 240TPH concentrator commissioning in September 2025 Solar expansion to 100 MW Phase 2 exploration and geophysics at DRC-bordering tenement ⸻ ABOUT TERRA METALS INC. Terra Metals Inc. is a Delaware-based mineral development company focused on securing high-impact, ESG- compliant critical mineral assets across Africa for delivery to U.S. and allied markets. MEDIA CONTACTS:Terra Metals IR@ +1 (980) 349-3883Website: Construction of 240 TPH Flotation Plant at Kalaba Mine A photo accompanying this announcement is available at:
Yahoo
4 minutes ago
- Yahoo
iDox.ai Launches Redaction Engine That Learns You: Personalized AI Now Available
AI-powered redaction software now adapts to document types, user behavior, and organization-specific needs with ongoing learning and customization features Fremont, California, June 09, 2025 (GLOBE NEWSWIRE) -- has launched a significant enhancement to its document redaction tool platform, Redact, with the introduction of Personalized AI, a suite of features that allows redaction tools to intelligently adjust based on document type, redaction history, and user Logo The Personalized AI update addresses the growing demand for smarter and more adaptable document processing in industries handling sensitive information, including legal, healthcare, finance, and law enforcement. Rather than relying on static rules, Redact now learns over time, providing users with redaction tools that become increasingly accurate and tailored to their workflows. Key components of the release include: Document Type Recognition: The AI automatically identifies document categories—such as contracts, medical records, or police reports—and adjusts its logic to match relevant redaction standards. This includes context-aware entity detection, like patient identifiers in medical files or license numbers in law enforcement records. Adaptive Entity Recognition: The system identifies and redacts sensitive content based on prior user actions, learning from ongoing redaction behavior to improve future performance. Regulation-Aware Data Profiles: Now supports a broad range of sensitive information types—including PII, PHI, racial covenants, and key business and financial data—with built-in awareness of compliance standards like HIPAA, GDPR, and FOIA. Manual Edits and Overrides: Users retain full control with the ability to fine-tune or override AI suggestions through a real-time editing interface. Whitelisting Functionality: Organizations can preserve specific terms or phrases from redaction, such as job titles or internal codes, improving accuracy and consistency. User and Team Learning: The system evolves with each user and team's redaction patterns, allowing it to provide more precise, context-appropriate suggestions as it accumulates insights. 'Our mission with Personalized AI is to deliver smarter, more human-aware redaction,' said Jeremy Wei, Founder of 'It's about context, control, and continuously improving performance tailored to each organization's needs.' The Personalized AI capabilities are now available to all current users of Redact. This release strengthens position at the forefront of AI-driven redaction by uniting adaptive personalization with deep regulatory awareness, enabling organizations to safeguard sensitive data while keeping pace with changing compliance requirements. About Designed for compliance-intensive environments, leverages artificial intelligence to automate and optimize document workflows across industries, with a primary focus on protecting sensitive data through features like PDF redaction, data security, and extraction. CONTACT: Gregory Sallis media@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
8 minutes ago
- Yahoo
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
- Composition of matter patent affirmed, provides protection into 2030 - Builds on recent ruling in favor of Acadia for formulation patent expiring in 2038 SAN DIEGO, June 09, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent established in Allergan USA, Inc. v. MSN Laboratories Private Ltd., MSN Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, holding that "a first filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date." "We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for NUPLAZID, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for NUPLAZID 34 mg capsule formulation into 2038," said Catherine Owen Adams, Chief Executive Officer. "These decisions reinforce our commitment to safeguarding the intellectual property that underpins our innovations in addressing serious, unmet medical needs." This follows the U.S. District Court for the District of Delaware ruling in favor of Acadia regarding its '721 formulation patent for NUPLAZID which ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New Drug Application) filers. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," "continue" and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the impact of the court ruling on our business and our ability to defend ourselves in the future; (ii) the continued patent protection for NUPLAZID; and (iii) the anticipated timing for termination of such protections. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our ability to maintain, protect and enhance our intellectual property; the outcome of other existing and potential future lawsuits challenging our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-Q for the quarter ended March 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law. View source version on Contacts Investor Contacts: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Media Contact: Acadia Pharmaceuticals Kazenelson(818) 395-3043media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
